Tag:
Strattera
Latest Headlines
Latest Headlines
Zydus claims right to launch Strattera copy
When Zydus Pharmaceuticals backed away from its patent fight with Eli Lilly ( $LLY ) over the ADHD drug Strattera in 2007, it created an opportunity to step forward three years later. While its eight
Lilly shares slide on second big patent setback
Eli Lilly ( NYSE: LLY ) has been hit with yet another key loss on the generic drug front, losing its case in federal court to protect its patent for the ADHD drug Strattera. And this one could prove
FDA approves Lilly's ADHD drug Strattera
Eli Lilly has won FDA approval of Strattera, a therapy designed to treat ADHD. Lilly says this is the first regulatory win for a non-stimulant ADHD drug in a market dominated by two
